Aktienanalyse zu Parabilis Medicines Inc (PBLS)PBLSParabilis Medicines Inc

Parabilis Medicines, Inc., formerly FOG Pharmaceuticals, Inc., is a clinical-stage biopharmaceutical company. It is built to develop transformative medicines addressing undruggable protein targets driving human disease. It leverages a proprietary platform to a novel therapeutic modality, Helicons, which are stabilized helical peptides engineered to bind and precisely modulate proteins that reach conventional medicine. Its lead product candidate, zolucatetide, is the first and only investigational therapy that inhibits the b-catenin: TCF interaction, the critical downstream node of the Wnt/b-catenin pathway. Its preclinical pipeline provides the Helicon approach and includes programs targeting two drivers of prostate cancer, the ETS-related gene and the androgen receptor (AR) in its active state (ARON). The Helicon discovery platform integrates advanced AI and physics-based computational modeling with peptide synthesis and experimental screening to discover and develop drug candidates. It operates in the Healthcare sector.

Parabilis Medicines Inc is not a good buy right now due to its extremely low RSI of 13.758, indicating oversold conditions, and a significant recent price drop of 17.21% over the last 5 days. While analysts have a bullish price target of $40-$45, the company has reported substantial losses, with a net income loss of $66,955,000 in Q2 2026, and a negative EPS of -0.54. The main risk is the high volatility, as evidenced by a 5-day change of -17.21%, which could lead to further declines before any potential recovery.